Xeltis is a leading brand that has developed the most advanced polymer-based platform for restorative cardiovascular devices. Their innovative technology allows for the natural evolution of their devices into living blood vessels or heart valves when colonized by a patient's own tissue. This groundbreaking approach is known as Endogenous Tissue Restoration (ETR).

With ETR, the patient's natural healing system creates tissue that permeates Xeltis' device, forming a new, fully functional blood vessel or heart valve. Xeltis' devices are made of bioabsorbable polymers, based on Nobel-prize awarded science, which enables them to be gradually absorbed by the body as ETR occurs. This unique feature sets Xeltis apart from other options currently available in the market.

Xeltis offers two main products: restorative heart valves and coronary bypass grafts. Their heart valves have the potential for long-term durability and growth, as they allow the body to develop new heart valves using the patient's own tissue. Similarly, their coronary bypass grafts offer a true alternative to vein harvesting, enabling the body to develop a new blood vessel and potentially reducing complications and overall healthcare costs.

With their cutting-edge technology and commitment to improving patients' lives, Xeltis is revolutionizing the field of cardiovascular restoration